iShares MSCI Israel ETF (EIS) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The stock last closed at $122.54. The rating moved from Oversold to Neutral on October 1, 2026.

• Public ratingNeutral (as of October 3, 2026)
• Last close$122.54
• Last changeMoved from Oversold to Neutral on October 1, 2026

AI analysis

EIS provides targeted exposure to Israeli equities with strengths in technology and healthcare but remains sensitive to regional geopolitical developments and global risk sentiment. Over a one-month horizon scenarios range from modest recovery if sentiment stabilizes to downside pressure if geopolitical tensions intensify.

Key factors

• Direct exposure to Israeli equities, which include meaningful weights in technology, healthcare and financials
• Heightened geopolitical sensitivity due to developments in the Middle East that can drive rapid flows and volatility
• Current market tone is risk-off with flows into defensive assets, limiting upside catalysts near term
• Currency dynamics (ILS vs USD) and global rate expectations can materially affect total returns for international equity exposure
• ETF structure provides diversified country exposure and generally good liquidity and low tracking error versus the benchmark

Risks

• Escalation of regional conflict leading to sharp outflows and sustained underperformance
• Concentration risk in a handful of large-cap technology and healthcare names
• Adverse currency moves for the Israeli shekel versus the U.S. dollar
• Global risk-off episodes or a deeper tech sector correction that disproportionately hurts Israeli exporters
• Policy or regulatory actions (domestic or international) that affect principal sectors
• Lower-than-expected earnings from major constituent companies

Latest MarketMoodz coverage

• Oil rally, defense stocks lead as Target earnings loom2026-03-02

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.